Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Summary

To compare continuing bevacizumab + paclitaxel or switching to bevacizumab + endocrine maintenance therapy followed by bevacizumab + paclitaxel, after 1st line induction therapy with bevacizumab + paclitaxel in ER+HER2- advanced or metastatic breast cancer.

Timeline

Start

2014-01

Primary completion

2018-06

Completion

2019-06

Outcome

Met primary endpoint

paper TFS was significantly longer in the endocrine therapy plus bevacizumab group than in the weekly paclitaxel plus bevacizumab group PMID 35405087 ↗

paper hazard ratio 0·51 [0·34-0·75]; p=0·0006 PMID 35405087 ↗

Publications

• Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anastrozole	Other / unclassified	—	—
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Exemestane	Small molecule	—	—
Subject	Fulvestrant	Small molecule	—	—
Subject	Goserelin	Other / unclassified	—	—
Subject	Letrozole	Other / unclassified	—	—
Subject	Leuprolide	Other / unclassified	—	—
Subject	Paclitaxel	Small molecule	90 mg/m2	Intravenous

Indications